CCL5 as a potential immunotherapeutic target in triple-negative breast cancer

被引:77
|
作者
Lv, Dandan [1 ]
Zhang, Yan [2 ]
Kim, Ha-Jeong [2 ]
Zhang, Lixing [1 ]
Ma, Xiaojing [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Sheng Yushou Ctr Cell Biol & Immunol, Shanghai 20040, Peoples R China
[2] Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY USA
关键词
triple negative breast cancer; CCL5; myeloid derived suppressor cell; immunotherapy; RANTES PROMOTER POLYMORPHISM; ALPHA-INDUCED SECRETION; SMOOTH-MUSCLE CELLS; GENETIC RISK-FACTOR; CHEMOKINE RANTES; MAMMARY-CARCINOMA; ELEVATED EXPRESSION; REGULATORY REGION; PROGNOSTIC-FACTOR; SUPPRESSOR-CELLS;
D O I
10.1038/cmi.2012.69
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-alpha (ER-alpha), progesterone receptor (PR) and HER-2/neu. About 15%-20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.
引用
收藏
页码:303 / 310
页数:8
相关论文
共 50 条
  • [21] Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker
    O'Conor, Christopher J.
    Chen, Tiffany
    Gonzalez, Ivan
    Cao, Dengfeng
    Peng, Yan
    BIOMARKERS IN MEDICINE, 2018, 12 (07) : 813 - 820
  • [22] CXCL16 as a potential therapeutic target of triple-negative breast cancer
    Cho, Sun Wook
    Jang, Mi Gyeong
    Sun, Hyun Jin
    Lee, Han Sai
    Song, Young Shin
    Kim, Seong Keun
    CANCER RESEARCH, 2022, 82 (04)
  • [23] CD74: a potential novel target for triple-negative breast cancer
    Tian, Buxian
    Zhang, Yuhong
    Li, Nan
    Liu, Xuewen
    Dong, Jianfeng
    TUMOR BIOLOGY, 2012, 33 (06) : 2273 - 2277
  • [24] SEPT3 as a Potential Molecular Target of Triple-Negative Breast Cancer
    Yang, Li-Hua
    Wang, Guo-Zhou
    Gao, Chao
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 1605 - 1613
  • [25] NOTCH4 Is a Potential Therapeutic Target for Triple-negative Breast Cancer
    Nagamatsu, Iori
    Onishi, Hideya
    Matsushita, Shojiro
    Kubo, Makoto
    Kai, Masaya
    Imaizumi, Akira
    Nakano, Kenji
    Hattori, Masami
    Oda, Yoshinao
    Tanaka, Masao
    Katano, Mitsuo
    ANTICANCER RESEARCH, 2014, 34 (1A) : 69 - 80
  • [26] BRAF: An emerging target for triple-negative breast cancer
    Albanell, Joan
    Elvin, Julia Andrea
    Ali, Siraj Mahamed
    Schrock, Alexa Betzig
    Chung, Jon
    Vergilio, Jo-Anne
    Suh, James
    Ramkissoon, Shakti
    Severson, Eric Allan
    Daniel, Sugganth
    Miller, Vincent A.
    Stephens, Philip J.
    Gay, Laurie M.
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] (+)-Dehydroabietylamine derivatives target triple-negative breast cancer
    Ling, Taotao
    Tran, My
    Gonzalez, Miguel A.
    Gautam, Lekh Nath
    Connelly, Michele
    Wood, Rachael K.
    Fatima, Iram
    Miranda-Carboni, Gustavo
    Rivas, Fatima
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 102 : 9 - 13
  • [28] Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications
    Shan, Jingxuan
    Chouchane, Aziz
    Mokrab, Younes
    Saad, Mohamad
    Boujassoum, Salha
    Sayaman, Rosalyn W.
    Ziv, Elad
    Bouaouina, Noureddine
    Remadi, Yasmine
    Gabbouj, Sallouha
    Roelands, Jessica
    Ma, Xiaojing
    Bedognetti, Davide
    Chouchane, Lotfi
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [29] Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5
    D'Esposito, Vittoria
    Liguoro, Domenico
    Ambrosio, Maria Rosaria
    Collina, Francesca
    Cantile, Monica
    Spinelli, Rosa
    Raciti, Gregory Alexander
    Miele, Claudia
    Valentino, Rossella
    Campiglia, Pietro
    De laurentiis, Michelino
    Di Bonito, Maurizio
    Botti, Gerardo
    Franco, Renato
    Beguinot, Francesco
    Formisano, Pietro
    ONCOTARGET, 2016, 7 (17) : 24495 - 24509
  • [30] INVESTIGATION OF POTENTIAL ROLE OF CCL5 IN BREAST CANCER PROGRESSION
    Hartmann, M. C.
    Dwyer, R. M.
    Costello, M.
    Kerin, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2010, 179 : 46 - 46